Theriva Biologics Gestion

Gestion contrôle des critères 1/4

Le PDG Theriva Biologics est Steve Shallcross, nommé en Jun2015, a un mandat de 9.42 ans. La rémunération annuelle totale est $ 1.27M, composée du salaire de 48.3% et des bonus 51.7%, y compris les actions et options de la société. détient directement 0.44% des actions de la société, d'une valeur de € 11.90K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 9.4 ans et 2.5 ans.

Informations clés

Steve Shallcross

Directeur général

US$1.3m

Rémunération totale

Pourcentage du salaire du PDG	48.3%
Durée du mandat du directeur général	9.4yrs
Propriété du PDG	0.4%
Durée moyenne d'occupation des postes de direction	9.4yrs
Durée moyenne du mandat des membres du conseil d'administration	2.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Steve Shallcross a-t-elle évolué par rapport aux bénéfices de Theriva Biologics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$22m
Mar 31 2024	n/a	n/a	-US$19m
Dec 31 2023	US$1m	US$614k	-US$18m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$1m	US$585k	-US$20m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$1m	US$585k	-US$23m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	n/a	n/a	-US$20m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$1m	US$565k	-US$13m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$1m	US$550k	-US$16m
Sep 30 2019	n/a	n/a	-US$28m
Jun 30 2019	n/a	n/a	-US$26m
Mar 31 2019	n/a	n/a	-US$27m
Dec 31 2018	US$963k	US$489k	-US$25m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$22m
Mar 31 2018	n/a	n/a	-US$22m
Dec 31 2017	US$799k	US$347k	-US$22m

Rémunération vs marché: La rémunération totale de Steve ($USD 1.27M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 471.14K ).

Rémunération et revenus: La rémunération de Steve a augmenté alors que l'entreprise n'est pas rentable.

PDG

Steve Shallcross (63 yo)

9.4yrs

Titularisation

US$1,271,913

Compensation

Mr. Steven A. Shallcross, also known as Steve, CPA, was an Independent Director of Forza X1, Inc. since December 2021. He served as Independent Director at Twin Vee Powercats Co. since April 8, 2021 until...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Steven Shallcross	CEO, CFO	9.4yrs	US$1.27m	0.44% € 11.9k
Vince Wacher	Head of Product & Corporate Development	no data	pas de données	pas de données
Michael Kaleko	Senior Vice President of Research & Development	12.1yrs	pas de données	pas de données
Ramon Alemany	Senior VP of Discovery & Chairman of Scientific Advisory Board	1.5yrs	pas de données	pas de données

9.4yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe dirigeante de SFY0 est chevronnée et expérimentée (9.4 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Steven Shallcross	CEO, CFO	5.9yrs	US$1.27m	0.44% € 11.9k
Ramon Alemany	Senior VP of Discovery & Chairman of Scientific Advisory Board	2.5yrs	pas de données	pas de données
John Monahan	Independent Director	4yrs	US$110.51k	0% € 0
Thomas Dubensky	Member of Scientific Advisory Board	2.5yrs	pas de données	pas de données
Jeffrey Kraws	Independent Non-Executive Chairman	18.8yrs	US$220.01k	0.0011% € 30.8
Mark Blumenkranz	Member of Scientific Advisory Board	2.5yrs	pas de données	pas de données
Jeffrey Wolf	Independent Director	18.8yrs	US$117.51k	0% € 0
Josep Tabernero Caturla	Member of Scientific Advisory Board	2.5yrs	pas de données	pas de données
Ennio Chiocca	Member of Scientific Advisory Board	2.5yrs	pas de données	pas de données
Daniel DiMaio	Member of Scientific Advisory Board	2.5yrs	pas de données	pas de données

2.5yrs

Durée moyenne de l'emploi

64.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la SFY0 n'est pas considéré comme expérimenté ( 2.5 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Theriva Biologics Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery

High number of new and inexperienced directors

Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022

Recent updates

Theriva Biologics, Inc. Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc. Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Theriva Biologics, Inc. has filed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

New major risk - Financial position

Theriva Biologics, Inc. Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation

Theriva Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $1.235303 million.

Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023

New minor risk - Shareholder dilution

New major risk - Market cap size

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery

Theriva Biologics, Inc. Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

High number of new and inexperienced directors

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004

Theriva Biologics, Inc. Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022

Synthetic Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.

Synthetic Biologics, Inc. Notifies Clearance of Safety Evaluation Period

High number of new and inexperienced directors

Synthetic Biologics, Inc. Reports Positive Safety Data on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Synthetic Biologics, Inc. Announces Peer-Reviewed Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients with Advanced Solid Tumors

Synthetic Biologics, Inc. (NYSEAM:SYN) signed a definitive agreement to acquire VCN Biosciences SL from Grifols Innovation and New Technologies Limited and others for $85.6 million.

Synthetic Biologics Provides Update on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

Synthetic Biologics, Inc. Announces Clinical Development and Operational Update

Insider recently bought €144k worth of stock

Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

New 90-day high: €1.23

Synthetic Biologics, Inc. Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

Synthetic Biologics, Inc. Announces Executive Changes

Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: €0.23

New 90-day low: €0.24

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2B Clinical Study of SYN-010 in IBS-C Patients

New 90-day low: €0.37

New 90-day high - €0.59

Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen